Download PDF
Semin intervent Radiol 2020; 37(05): 499-507
DOI: 10.1055/s-0040-1720951
Review Article

Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy

Evan D. Lehrman
1   Division of Interventional Radiology, Department of Radiology, University of California, San Francisco, California
,
Nicholas Fidelman
1   Division of Interventional Radiology, Department of Radiology, University of California, San Francisco, California
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Neuroendocrine tumor liver metastases are treated by a multidisciplinary cohort of physicians that work together to achieve optimal clinical results for their patients. This review addresses critical concepts in diagnosis and workup of such patients followed by medical, surgical, and liver-directed arterial and ablative therapies. Specific perioperative care for these patients is crucial in avoiding dreaded complications related to Carcinoid Crisis. The recent introduction of Peptide Receptor Radionuclide Therapy as a therapeutic option has impacted some of the algorithms for timing and selection of arterial embolotherapies.

Keywords

neuroendocrine tumor - carcinoid crisis - chemoembolization - radioembolization - bland embolization - ablation - peptide receptor radionuclide therapy

Disclosures

N.F. has received research grants from Merck, Sitex, and Boston Scientific.




Publication History

Article published online:
11 December 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
    CrossrefPubMedSearch in Google Scholar
  • 2 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97 (04) 934-959
    CrossrefPubMedSearch in Google Scholar
  • 3 Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19 (10) 1727-1733
    CrossrefPubMedSearch in Google Scholar
  • 4 Deroose CM, Hindié E, Kebebew E. et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med 2016; 57 (12) 1949-1956
    CrossrefPubMedSearch in Google Scholar
  • 5 Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2008; 2 (03) 113-125
    PubMedSearch in Google Scholar
  • 6 Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014: 13-27
    CrossrefPubMedSearch in Google Scholar
  • 7 Zuetenhorst JM, Bonfrer JMGM, Korse CM, Bakker R, van Tinteren H, Taal BG. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003; 97 (07) 1609-1615
    CrossrefPubMedSearch in Google Scholar
  • 8 Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME, Davar J. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 2011; 107 (08) 1221-1226
    CrossrefPubMedSearch in Google Scholar
  • 9 Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340 (11) 858-868
    CrossrefPubMedSearch in Google Scholar
  • 10 Kahil ME, Brown H, Fred HL. The carcinoid crisis. Arch Intern Med 1964; 114: 26-28
    CrossrefPubMedSearch in Google Scholar
  • 11 Marsh HM, Martin Jr JK, Kvols LK. et al. Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology 1987; 66 (01) 89-91
    CrossrefPubMedSearch in Google Scholar
  • 12 Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 2012; 17 (05) 725-731
    CrossrefPubMedSearch in Google Scholar
  • 13 Sinha V, Dyer P, Shuvro R-C, Geh JI, Karandikar S. Case of carcinoid crisis following a fine-needle biopsy of hepatic metastasis. Eur J Gastroenterol Hepatol 2009; 21 (01) 101-103
    CrossrefPubMedSearch in Google Scholar
  • 14 Morrisroe K, Sim I-W, McLachlan K, Inder WJ. Carcinoid crisis induced by repeated abdominal examination. Intern Med J 2012; 42 (03) 342-344
    CrossrefPubMedSearch in Google Scholar
  • 15 Rinke A, Müller HH, Schade-Brittinger C. et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27 (28) 4656-4663
    CrossrefPubMedSearch in Google Scholar
  • 16 Shah MH, Goldner WS, Halfdanarson TR. et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 2018; 16 (06) 693-702
    CrossrefPubMedSearch in Google Scholar
  • 17 Kaltsas G, Caplin M, Davies P. et al; Antibes Consensus Conference participants. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology 2017; 105 (03) 245-254
    CrossrefPubMedSearch in Google Scholar
  • 18 Kwon DH, Paciorek A, Mulvey CK. et al. Periprocedural management of patients undergoing liver resection or embolotherapy for neuroendocrine tumor metastases. Pancreas 2019; 48 (04) 496-503
    CrossrefPubMedSearch in Google Scholar
  • 19 Howe JR, Cardona K, Fraker DL. et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas 2017; 46 (06) 715-731
    CrossrefPubMedSearch in Google Scholar
  • 20 Mayo SC, de Jong MC, Pulitano C. et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17 (12) 3129-3136
    CrossrefPubMedSearch in Google Scholar
  • 21 Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery 2018; 163 (01) 218-225
    CrossrefPubMedSearch in Google Scholar
  • 22 Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?. Surgery 2016; 159 (01) 320-333
    CrossrefPubMedSearch in Google Scholar
  • 23 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedSearch in Google Scholar
  • 24 Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am 2016; 30 (01) 179-191
    CrossrefPubMedSearch in Google Scholar
  • 25 Danthala M, Kallur KG, Prashant GR, Rajkumar K, Raghavendra Rao M. (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years' experience from a tertiary cancer care centre in India. Eur J Nucl Med Mol Imaging 2014; 41 (07) 1319-1326
    CrossrefPubMedSearch in Google Scholar
  • 26 de Keizer B, van Aken MO, Feelders RA. et al. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2008; 35 (04) 749-755
    CrossrefPubMedSearch in Google Scholar
  • 27 Bhagat N, Reyes DK, Lin M. et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 2013; 36 (02) 449-459
    CrossrefPubMedSearch in Google Scholar
  • 28 Vogl TJ, Naguib NNN, Zangos S, Eichler K, Hedayati A, Nour-Eldin N-EA. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72 (03) 517-528
    CrossrefPubMedSearch in Google Scholar
  • 29 Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials 2018; 19 (01) 390
    CrossrefPubMedSearch in Google Scholar
  • 30 Yang H, Seon J, Sung PS. et al. Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma: a randomized, double-blinded, placebo-controlled study. J Vasc Interv Radiol 2017; 28 (11) 1503-1511.e2
    CrossrefPubMedSearch in Google Scholar
  • 31 Tomozawa Y, Jahangiri Y, Pathak P. et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol 2018; 29 (06) 858-865
    CrossrefPubMedSearch in Google Scholar
  • 32 Su YK, Mackey RV, Riaz A. et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol 2017; 28 (11) 1520-1526
    CrossrefPubMedSearch in Google Scholar
  • 33 Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol 2019; 30 (12) 1915-1923
    CrossrefPubMedSearch in Google Scholar
  • 34 Devulapalli KK, Fidelman N, Soulen MC. et al. 90Y radioembolization for hepatic malignancy in patients with previous biliary intervention: multicenter analysis of hepatobiliary infections. Radiology 2018; 288 (03) 774-781
    CrossrefPubMedSearch in Google Scholar
  • 35 Khan W, Sullivan KL, McCann JW. et al. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol 2011; 197 (02) W343-5
    CrossrefPubMedSearch in Google Scholar
  • 36 Chen JX, Rose S, White SB. et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol 2017; 40 (01) 69-80
    CrossrefPubMedSearch in Google Scholar
  • 37 Mohan H, Nicholson P, Winter DC. et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 2015; 26 (07) 935-942.e1
    CrossrefPubMedSearch in Google Scholar